AIDS vaccine nears human testing

Aug 31, 2006

A University of Kansas Medical Center researcher hopes to get the funds needed for the next step in developing his AIDS vaccine -- testing on humans.

Attention is focused on the university's Bill Narayan whose experimental vaccine kept monkeys from getting sick after being infected with a variety of the AIDS virus, The Kansas City (Mo.) Star said. A study on the vaccine appeared this month in the journal Virology.

Narayan is waiting for word from the National Institutes of Health on whether he will get the $20 million needed to manufacture the vaccine and test it on people.

Copyright 2006 by United Press International

Explore further: Recorded Ebola deaths top 7,000

add to favorites email to friend print save as pdf

Related Stories

AIDS Vaccine Progress Published in Virology

Sep 06, 2006

A University of Kansas School of Medicine researcher’s success developing an AIDS vaccine was reported in the August issue of the peer-reviewed journal Virology. Opendra Narayan, DVM, PhD, and his collaborators have succes ...

Recommended for you

Restrictions lifted at British bird flu farm

2 hours ago

Britain on Sunday lifted all restrictions at a duck farm in northern England after last month's outbreak of H5N8 bird flu, the same strain seen in recent cases across Europe.

Recorded Ebola deaths top 7,000

Dec 20, 2014

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.